Skip to Content


Virtual Osteosarcoma and Ewing’s Sarcoma Center

CCH Newsletter - Fall 2010

For patients with sarcomas, MD Anderson has long been a leading source for excellent treatment and research expertise. Now, that standard of excellence will be taken to a new level with the creation of the Virtual Osteosarcoma and Ewing’s Sarcoma Center, which will be directed by Peter Anderson, M.D., Ph.D., section chief of sarcoma within the Children’s Cancer Hospital.


What is the Virtual Osteosarcoma and Ewing’s Sarcoma Center?

The Virtual Osteosarcoma and Ewing’s Sarcoma Center is a referral center that will oversee the care of children and adults with osteosarcoma and Ewing’s sarcoma at MD Anderson. The center provides multidisciplinary care to patients from a variety of specialists as well as access to any relevant protocols available at MD Anderson – all within one center.

How will patients be seen at the center?

Facilitated through MD Anderson Children’s Cancer Hospital and directed by Peter Anderson, M.D., Ph.D., each patient’s case will be reviewed by a committee of pediatric oncologists, medical oncologists and orthopedic surgeons, all of whom specialize in sarcoma care. The committee will confer on a patient’s diagnosis, evaluate available protocols and collectively decide on the best treatment plan for the patient. Once a course of treatment is determined, patients will receive care where most appropriate, either within the Children’s Cancer Hospital or 
MD Anderson’s adult sarcoma department.

How will the center benefit patients?

Patients referred through the center will benefit from an expert panel of oncologists and surgeons focused on the treatment of osteosarcoma and Ewing’s sarcoma. In addition, patients will receive comprehensive care from dedicated specialists, including physical therapists, research assistants, child life specialists for adolescents and young adults, education specialists and psychologists, to improve the overall experience of bone cancer patients.

From this streamlined process of care, enrollment on clinical protocols will be more efficient. Decisions can be made sooner as to which protocols to bring to the frontlines for newly diagnosed patients. In addition, sarcoma researchers will work collaboratively with clinicians to translate their laboratory research into new clinical trials, which will benefit patients with relapsed or refractory sarcomas. Overall, the Virtual Osteosarcoma and Ewing's Sarcoma Center will ensure that all of the extensive resources and expertise at MD Anderson will be available to every patient with these rare sarcomas.

© 2015 The University of Texas MD Anderson Cancer Center